PROTAC CARM1/IKZF3 degrader-1 

PROTAC CARM1/IKZF3 degrader-1 (Compound 074) inhibits CARM1, reduces the methylation level of its substrate BAF155. PROTAC CARM1/IKZF3 degrader-1 is the PROTAC degrader for IKZF 1/3 through a CRBN-dependent pathway. PROTAC CARM1/IKZF3 degrader-1 inhibits the expression of MYC protein, thereby inhibiting the proliferation of a variety of multiple myeloma cells. PROTAC CARM1/IKZF3 degrader-1 induces apoptosis in cell H929. PROTAC CARM1/IKZF3 degrader-1 overcomes immunomodulatory drugs (IMiD, such as pomalidomide) resistance. PROTAC CARM1/IKZF3 degrader-1 can be used in cancer and immunology research^[1]. (Pink: ligand for target protein CARM1/IKZF3 ligand 1 (HY-172369); Active form of target protein ligand: EZM 2302 (HY-111109); Black: linker (HY-21999); Blue: ligand for E3 ligase Cereblon Thalidomide 4-fluoride (HY-41547)) (Pink: CARM1 and IKZF3 ligand (HY-172369); Blue: Cereblon ligand (HY-41547); Black: linker (HY-21999)).

896.43

C₄₆H₅₄ClN₉O₈

ClC1=C(C2=NC(C3=C(C)ON=C3C)=C(C)C(N4CC5(CCN(C(CCCCCNC6=C(C(N(C7C(NC(CC7)=O)=O)C8=O)=O)C8=CC=C6)=O)CC5)C4)=N2)C=C(OC[C@@H](CNC)O)C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ni W, et al. Dual CARM1-and IKZF3-targeting: a novel approach to multiple myeloma therapy Synergy between CARM1 inhibition and IMiDs[J]. Molecular Therapy Oncology, 2025.